Canada • TSX Venture Exchange • TSX-V:KHRN • CA49374L3065
The current stock price of KHRN.CA is 0.04 CAD. In the past month the price decreased by -11.11%. In the past year, price decreased by -75%.
ChartMill assigns a fundamental rating of 2 / 10 to KHRN.CA. KHRN.CA has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months KHRN.CA reported a non-GAAP Earnings per Share(EPS) of -0.17. The EPS decreased by -59.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.05 |
7 analysts have analysed KHRN.CA and the average price target is 0.1 CAD. This implies a price increase of 155% is expected in the next year compared to the current price of 0.04.
For the next year, analysts expect an EPS growth of 39.13% and a revenue growth 36.43% for KHRN.CA
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| BHC | BAUSCH HEALTH COS INC | 1.43 | 3.019B | ||
| GSD | DEVONIAN HEALTH GROUP INC | N/A | 1.659B | ||
| CRON | CRONOS GROUP INC | 37.36 | 1.367B | ||
| TLRY | TILRAY BRANDS INC | N/A | 1.211B | ||
| DHT-UN | DRI HEALTHCARE TRUST | 7.02 | 902.702M | ||
| GUD | KNIGHT THERAPEUTICS INC | 122.36 | 590.775M | ||
| WEED | CANOPY GROWTH CORP | N/A | 552.69M | ||
| NGEN | NERVGEN PHARMA CORP | N/A | 393.546M | ||
| CPH | CIPHER PHARMACEUTICALS INC | 26.94 | 370.148M | ||
| TSND | TERRASCEND CORP | N/A | 331.425M |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the TSX Venture Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find more growth stocks the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
Khiron Life Sciences Corp. is a vertically integrated medical and consumer packaged goods (CPG) cannabis company with core operations in Latin America and operational activities in Europe and North America. The company is headquartered in Toronto, Ontario and currently employs 310 full-time employees. The company went IPO on 2012-10-25. The Company’s product lines include medical cannabis products, health services and wellbeing products. The medical cannabis product sells branded medical cannabis products. The health service operates its own network of medium complexity health centers (operating under the ILANS and Zerenia brands) and Zerenia satellite clinics offering a range of health, medical and surgical services in alignment with insurance company partners. Its wellbeing product is focused on delivering the benefits of cannabidiol (CBD) a range of various branded consumer packaged goods, such as its Kuida cosmetics line. The firm provides patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure. The firm sells its products in Colombia, Peru, Germany, United Kingdom and Brazil.
KHIRON LIFE SCIENCES CORP
100 King St.W., Suite 1600, 1 First Canadian Place
TORONTO ONTARIO V6C 2B5 CA
CEO: Alvaro Torres
Employees: 310
Phone: 17055273564.0
Khiron Life Sciences Corp. is a vertically integrated medical and consumer packaged goods (CPG) cannabis company with core operations in Latin America and operational activities in Europe and North America. The company is headquartered in Toronto, Ontario and currently employs 310 full-time employees. The company went IPO on 2012-10-25. The Company’s product lines include medical cannabis products, health services and wellbeing products. The medical cannabis product sells branded medical cannabis products. The health service operates its own network of medium complexity health centers (operating under the ILANS and Zerenia brands) and Zerenia satellite clinics offering a range of health, medical and surgical services in alignment with insurance company partners. Its wellbeing product is focused on delivering the benefits of cannabidiol (CBD) a range of various branded consumer packaged goods, such as its Kuida cosmetics line. The firm provides patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure. The firm sells its products in Colombia, Peru, Germany, United Kingdom and Brazil.
The current stock price of KHRN.CA is 0.04 CAD.
KHRN.CA does not pay a dividend.
KHRN.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
KHIRON LIFE SCIENCES CORP (KHRN.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.17).
The Revenue of KHIRON LIFE SCIENCES CORP (KHRN.CA) is expected to grow by 36.43% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
KHIRON LIFE SCIENCES CORP (KHRN.CA) has a market capitalization of 7.19M CAD. This makes KHRN.CA a Nano Cap stock.